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Progesterone (Pg) and estrogen (E) receptors (PgRs and ERs) are expressed in normal
and neoplastic adrenal cortex, but their role is not fully understood. In literature, Pg
demonstrated cytotoxic activity on AdrenoCortical Carcinoma (ACC) cells, while tamoxifen
is cytotoxic in NCI-H295R cells. Here, we demonstrated that in ACC cell models, ERs
were expressed in NCI-H295R cells with a prevalence of ER-b over the ER-a.Metastasis-
derived MUC-1 and ACC115m cells displayed a very weak ER-a/b signal, while PgR cells
were expressed, although at low level. Accordingly, these latter were resistant to the
SERM tamoxifen and scarcely sensitive to Pg, as we observed a lower potency compared
to NCI-H295R cells in cytotoxicity (IC50: MUC-1 cells: 67.58 µM (95%CI: 63.22–73.04),
ACC115m cells: 51.76 µM (95%CI: 46.45–57.67) and cell proliferation rate. Exposure of
NCI-H295R cells to tamoxifen induced cytotoxicity (IC50: 5.43 µM (95%CI: 5.18–5.69 µM)
mainly involving ER-b, as their nuclear localization increased after tamoxifen: D A.U. treated
vs untreated: 12 h: +27.04% (p < 0.01); 24 h: +36.46% (p < 0.0001). This effect involved the
SF-1 protein reduction: Pg: −36.34 ± 9.26%; tamoxifen: −46.25 ± 15.68% (p < 0.01).
Finally, in a cohort of 36 ACC samples, immunohistochemistry showed undetectable/low
level of ERs, while PgR demonstrated a higher expression. In conclusion, ACC experimental
cell models expressed PgR and low levels of ER in line with data obtained in patient tissues,
thus limiting the possibility of a clinical approach targeting ER. Interestingly, Pg exerted
cytotoxicity also in metastatic ACC cells, although with low potency.
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INTRODUCTION
Adrenocortical carcinoma (ACC) is a rare and aggressive tumor
with an incidence of 0.7–2 new cases per million populations per
year (1). Early diagnosis followed by radical surgical resection
associated or not with adjuvant mitotane therapy (2, 3) is the
only option that can give to ACC patients a chance of cure (4).
The standard systemic treatment for advanced/metastatic ACC
patients, not eligible to surgery, is mitotane, which is
administered either alone or in combination with Etoposide,
Doxorubicin, and Cisplatin (EDP-M regimen) (5). Although
some pathological responses have been observed (6), the
efficacy of EDP-M is limited and most initially responding
patients are destined to relapse and die of the disease. Other
cytotoxic therapies administered to patients with disease
progression to EDP-M did not show a remarkable activity (7,
8). Molecular target therapies, attempted up to now (9), and
immunotherapy (10) appeared ineffective.
Progesterone receptors (PgRs) and estrogen receptors
(ERs) are expressed at different intensities in both normal and
neoplastic adrenal cortex (11); however, the patho-physiological
relevance of the steroid receptor expression in the physiological
regulation of adrenal cell proliferation is not yet fully understood.
In particular, in adulthood, ER-b is expressed in the glomerular
and fasciculated area of the adrenal cortex, while at the
prepubertal age, it is mainly located in the reticular area (12,
13). The ER-a subtype appears to be poorly expressed. During
the course of neoplastic degeneration, there is an unpredictable
rearrangement of the expression of these receptors, and data
concerning the expression of the ERs are controversial. Indeed, a
negativity for ER-a and an increase of the ER-b in the
AdrenoCortical Carcinoma (ACC) have been reported by
immunohistochemical analysis (11), while a decrease of ER
expression has been observed as the ACC progresses (14, 15).
Finally, other studies demonstrated low ER-b levels and/or high
levels of ER-a in numerous cases of ACC, leading to an increase
in the ER-a/ER-b ratio compared to that observed in healthy
tissue (13). In the NCI-H295R cells, it was observed that ER-b
gene expression is higher compared to ER-a, and the selective
estrogen receptor modulator (SERM) 4-OH-tamoxifen inhibits
cell proliferation (16).
The expression of ER subtypes varies in different tissues,
although they are often co-expressed (17). The traditional
paradigm is that ER-a is oncogenic and increases cell survival,
while ER-b exerts an opposite role, being protective and pro-
apoptotic. This clear distinction, however, cannot be applied for
each tissue and cell expressing both ER subtypes; indeed, ER-a
has a dominant role in tissues such as the uterus, mammary
glands, pituitary, skeletal muscle, adipose, and bone; whereas,
ER-b has a major role in the ovary, prostate, lung, cardiovascular,
and central nervous systems (17).
PgR expression was as well detected in ACC (11). Recently,
our group demonstrated a cytotoxic effect of Pg in ACC cells
(18). Pg treatment of NCI-H295R cells induced apoptosis via
activation of PgR with the involvement of both genomic and
non-genomic pathways.
In breast cancer cells, PgR is a transcriptional target of ER,
and estrogen is well known to be an important stimulator of PgR
synthesis (19). Similar results have been obtained in human
endometrial carcinoma (20). Interestingly, in a rare and peculiar
setting such as pregnancy in ACC patients, in which there are
elevated levels of both Pg and E hormones, their role in the
control/progression of the disease is controversial. Indeed a study
in 12 pregnant ACC patients concluded that pregnancy is
associated with shorter survival and disease-free survival
compared to control group (21), while another study on 17
treated ACC patients becoming pregnant during the follow-up,
the pregnancy seems to be not associated with worse clinical
outcome (22). As the authors correctly pointed out, however,
pregnancy-associated ACC tended to be discovered at a more
advanced stage. Thus, the possibility of a pregnancy-induced
more rapid progression cannot be excluded, and we would like to
underline that diagnostic and therapeutic delays probably
account for the most severe presentation. Tamoxifen and
medroxy-progesterone acetate combined treatment exhibited
significant inhibitory growth effect on breast cancer (23),
endometrial cancer (24), and cisplatin-resistant ovarian cancer
cells (25). This combination therapy appeared to be active in
phase II studies enrolling endometrial carcinoma patients (26).
These data provided the rationale to explore the cytotoxic
interaction between selective estrogen receptor modulators
(SERMs), such as tamoxifen, and Pg in ACC.
Here, we explored the possible effect of tamoxifen on ACC
cell viability and investigated the additive/synergic cytotoxic




The human NCI-H295R cell line, derived from a primitive ACC
in a female patient (27), was obtained from the American Type
Culture Collection (ATCC) and cultured as indicated by ATCC.
MUC-1 cell line, established form a neck metastasis of an EDP-
M treated male patient, was kindly given by Dr. Hantel and
cultured as suggested (28). Media and supplements were
supplied by Sigma Aldrich Italia, (Milan, Italy).
Primary ACC Cell Culture
Human ACC primary cells were derived from a male patient who
underwent surgical removal of metastatic ACC, in progression
after EDP-M. The local Ethical Committee approved the project
and written informed consent was obtained from the patient.
The primary culture ACC115m was obtained as previously
described (29) and maintained in MUC-1 medium
supplemented with L-Glutamine (2 mM) and amphotericin B
(2.5 mg/ml). The clinical characteristics of the patient are
reported in Supplemental Table 1. Cells were tested for
mycoplasma and authenticated from BMR genomics
(Padova, Italy).
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Immunohistochemistry
Tissue samples were obtained from formalin-fixed and paraffin
embedded blocks from surgical samples. 2 mm thick sections
were used for routine Hematoxylin and Eosin (H&E) staining
and immunohistochemistry using the automatic stainer
BenchMark ULTRA IHC/ISH System (Ventana). Diagnosis of
cortical cell carcinoma was revised according to the most recent
WHO criteria (30). The clinical characteristics of the patient are
reported in Supplemental Table 1. The following primary
antibodies were used: anti-PgR clone 1E2, anti-ER clone SP1.
All the primary antibodies were from “ready to use” kits from
Ventana. Antigen retrieval was performed by incubation for
64 min for PgR and ER at 95°C in Ultra Cell Conditioning
Solution (Ultra CC1, Ventana). Signal was revealed using the
ultraView Universal DAB Detection kit (Ventana) followed by
diaminobenzydine as chromogen and Hematoxylin for nuclear
counterstain. Digital images were acquired by an Olympus XC50
camera mounted on a BX51 microscope (Olympus, Tokyo,
Japan) using CellF Imaging software (Soft Imaging System
GmbH, Münster, Germany). Expression of PR and ER was
semi-quantitatively scored on representative tumor areas
based on both percentage [score ranges: 0 (0–5%), 1 (6–29%),
2 (30–69%), 3 (≥70%)] and intensity (score ranges: 0, no
expression; 1, weak; 2, moderate; 3, high) of immunoreactive
(IR) neoplastic cells.
Immunofluorescence
Cells were grown onto 12 mm poly-L-lysine coated coverslips
for 4 days and were then fixed with paraformaldehyde 4% (w/v)
(Immunofix, Bio-Optica, Milan, Italy) for 15 min at 4°C and
permeabilized with 20% MetOH and 0.1% Triton X-100 in PBS
for 10 min. Non-specific binding was blocked by incubation in
PBS containing 0.1% Triton X-100 and 0.2% of BSA for 45 min.
Cells were incubated with anti-PgR (raised in rabbit, 1:800, Cell
Signaling Technology, Denvers, MA, USA), anti-ER-b (raised in
rabbit, 1:500, Abcam, Cambridge, United Kingdom) and anti-
ER-a (raised in mouse, 1:500, Invitrogen, Carlsbad, CA, USA)
primary antibodies o/n at 4°C. After extensive washes, the anti-
rabbit Alexa Fluor 488 (green signal) and anti-mouse Alexa Fluor
555 (red signal) (Immunological Sciences, Rome, Italy)
secondary antibodies, and Alexa Fluor 647 Phalloidin
(Invitrogen) were applied for 1 h at rt. After rinsing in PBS,
coverslips were mounted using DAPI-containing Vectashield
mounting medium (Vector Laboratories, Burlingame, CA, USA).
Slides were observed by a LSM 880 Zeiss confocal laser
microscope equipped with Plan-Apochromat 63×/1.4
numerical aperture oil objective or by a LSM 510 Zeiss
confocal laser microscope (Carl Zeiss AG, Oberkochen,
Germany) equipped with Plan-Apochromat 63×/1.4 numerical
aperture oil objective. Images were then reconstructed using
Zeiss ZEN 2.3 Imaging Software (Carl Zeiss). The specific mean
fluorescence intensity of the pixels was quantified using ZEN
Black software (Carl Zeiss) and/or ImageJ software (Nation
Institute of Health. Bethesda, MD, USA). Several fields,
randomly chosen, were acquired and analyzed for each
experimental condition.
Cell Treatments
Cells were treated with increasing concentrations of progesterone
(0.1–160 µM; Merck Serono, Milan, Italy) and tamoxifen (0.1–
20 µM; Selleckchem Chemicals-DBA Italia, Segrate, Milan, Italy);
both drugs were solubilized in DMSO. Preliminary experiments
of concentration–response curves were conducted in the ACC
cell cultures in order to establish the optimal drug concentration
range and length of treatment. All experiments were conducted
in charcoal-dextran-treated serum (CTS).
Measurement of Cell Viability
and Proliferation
Cell viability was assessed by 3-(4,5-Dimethyl-2-thiazol)-2,5-
diphenyl-2H-tetrazolium bromide (MTT) dye reduction assay
as described in Fiorentini et al. (31). Briefly, untreated and drug-
treated cells were incubated withMTT dye (at final concentration
of 0.5 mg/ml) and solubilized with DMSO. Absorbance was
determined at 540/620 nm by a spectrophotometer (GDV, Rome,
Italy). Cell proliferation rate was evaluated with TC20 automated
cell counter (Bio-Rad Laboratories, Segrate, Milan, Italy). Briefly,
cells were grown in 24-well plates, dislodged by trypsinization
and suspended in culture medium followed by trypan blue
dilution (1:2). The parameter settings were established
according to the manufacturer’s instructions. 10 µl of sample
was loaded into a slide and counted.
Drug Combination Experiments
Combination experiments were performed to evaluate the
interaction of Pg and tamoxifen on cell viability according to the
Chou and Talalay method (32). Cells were treated for 4 days using
increasing concentrations of progesterone (7.4–84.3 µM), tamoxifen
(0.8–13.5 µM), and mitotane (1.51–17.21 µM) as single drug and in
combination, as recommended for the most efficient data analysis
(33). The drug concentration curve for the combination has been
designed for each ACC cell model based on the respective IC50 of
each drug. Data were then converted to Fraction affected (Fa, range
from 0 to 1 where Fa = 0 indicating 100% cell viability and Fa = 1
indicating 0% cell viability) and analyzed using the CompuSyn
software (ComboSyninc. Paramus, NJ, USA) to calculate the
Combination Index (CI). A CI value <1, = 1, and >1 indicates
synergism, additive effect, and antagonism respectively.
Quantitative RT-PCR
Gene expression was evaluated by q-RT-PCR (ViiA7, Applied
Biosystems, Milan, Italy) using SYBR Green as fluorochrome as
described elsewhere (34). Sequences of oligonucleotide primers
were reported in Supplemental Table 2. Reactions were
performed under the following conditions: 1 cycle at 95°C for
10 min, 40 cycles at 95°C for 15 s, 62°C for 1 min. Differences of
the threshold cycle (Ct) values between the b actin housekeeping
gene and the gene of interest (DCt) were then calculated.
miRNA Analysis
Total RNA, including miRNAs, was extracted from cells using
the miRNeasy kit (Qiagen, Milan, Italy), and 1 µg was
transcribed into cDNA using miScript II RT kit (Qiagen),
following the manufacturer’s protocol. q-RT-PCR was
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performed with a miScript System (Qiagen) (35). Reactions were
performed under the following conditions: 95°C 15 min; 94°C
15 s, 55°C 30 s, 70°C 30 s, 40 cycles. Sequences of miR-23 used
were : miR23a : 5 ′AUCACAUUGCCAGGGAUUUCC;
miRNA23b: 5′AUCACAUUGCCAGGGAUUACC. Variations
in expression of miR-23a/b among different samples were
calculated after normalization to U6.
Western Blot
Cells were homogenized in cold RIPA buffer, and total protein
concentrations were determined by Bio-Rad Protein Assay (Bio-
Rad Laboratories). Proteins (30 mg/lane) were separated by
electrophoresis on a 4–12% NuPAGEbis-tris gel system (Life
Technologies, Milan, Italy) and electroblotted to a nitrocellulose
membrane. Membranes were incubated with an anti-SF1 (0.234
µg/ml; Cell Signaling Technology) and anti-GAPDH (1 µg/ml
Merk Millipore, Burlington, MA, USA) primary antibodies
according to the manufacturer’s instructions. Secondary HRP-
labeled anti-mouse and anti-rabbit antibodies (Santa Cruz
Biotechnologies, Heidelberg, Germany) were used, and the
specific signal was visualized using a Westar ECL Sun Western
blot substrate (Cyanagen, Bologna, Italy). Densitometric analysis
of the immunoblots was performed using NIH ImageJ Software.
Statistical Analysis
The analysis of the data was carried out by the GraphPad Prism
version 5.02 software (GraphPad Software, La Jolla, CA) using
the one-way ANOVA with Bonferroni’s multiple comparisons
test considering P < 0.05 as threshold for significant difference.
IC50 values for each drug were calculated by non-linear
regression of the concentration–response curves. All results are
expressed as mean ± SEM of three independent experiments,
unless otherwise specified. Cytotoxicity experiments were carried
out at least three times, each point run in triplicate.
RESULTS
Estrogens in the ACC Cell Models
Due to the suggested different roles of ER in cell viability, we
evaluated whether the ER-a and ER-b subtypes were differentially
expressed in ACC experimental cell models. ACC cell lines and
the ACC115m primary cell culture were then investigated for ER
gene and protein subtype expression. Results on gene expression
are reported in Table 1, while the mRNA translation into the
respective protein was demonstrated by immunofluorescence and
reported in Figure 1 and quantified in Supplemental Figure 1.
Concerning the ACC cell lines, NCI-H295R cells expressed both
ER subtypes, although the gene and the protein both indicated a
low level of expression with a prevalence of ER-b over the ER-a
(Figure 1A, Supplemental Figures 1, 2). Metastasis-derived
MUC-1 cell line and ACC115m primary culture, displayed a
very weak expression of ER-a and ER-b, both at gene (Table 1)
and protein levels (Figure 1; quantified in the Supplemental
Figure 1). We would like to underline the peculiar sub-cellular
localization of the ER subtypes as we can observe a prevalent
nuclear localization of ER-b.
NCI-H295R cell line expressed the CYP19A1 enzyme (31)
and produced 17b-estradiol (10.01 ± 0.77 ng/ml; Supplemental
Methods). As it has been shown that exogenous administration
induced cell growth [16 and unpublished data], to explore the
possible involvement of ERs in ACC cytotoxicity and cell
proliferation rate, ACC cells were treated with increasing
concentrations of tamoxifen for 4 days and then evaluated for
cell viability. The ACC cell line NCI-H295R displayed a
concentration-dependent cytotoxicity, with the IC50 of 5.43 µM
(95% CI: 5.18–5.69 µM) (Figure 2A) and the reduction of the cell
proliferation rate (Figure 2B). MUC-1 cell line and ACC115m
primary culture resulted resistant to tamoxifen (Supplemental
Figure 3), accordingly to the very low ER expression in these
ACC cell models. In particular, tamoxifen exposure did not show
any effect on cell viability up to 15 µM and then a sharp decrease
at 17.5 µM and 20 µM, more evident in ACC115m. Whether this
effect is ER-dependent or not needs to be determined.
Tamoxifen Induced ER-b Nuclear
Translocation in NCI-H295R Cell Line
To evaluate whether the tamoxifen effect involved a selective
subtype, NCI-H295R cells were exposed to the drug IC50, and
cells were fixed and analyzed at the confocal microscope at
different times. Figure 3A shows that tamoxifen treatment
induced a time-dependent increase of nuclear signal of ER-b,
thus suggesting a significant nuclear translocation after 12 h of
drug exposure that was maintained up to 24 h (Figure 3B),
without any modification of the amount and localization of ER-a
(Supplemental Figure 4). These results suggested that ER-b
could be the subtype mainly involved in the tamoxifen effect.
Pg in the ACC Cell Models
We already demonstrate that NCI-H295R cells express PgR (31)
and that Pg exerts a concentration-dependent cytotoxic effect on
NCI-H295R cells line as well as in ACC primary cell cultures
expressing PgR (18). Here, we confirmed this result in other ACC
cell models, studying the Pg effect in metastasis-derived cell
models, namely MUC-1 cell line and in ACC115m primary cells.
We firstly assessed the PgR expression in these cells by q-RT-
PCR. The DCt obtained was MUC-1: 12.71 ± 0.62; ACC115m:
10.39 ± 0.04 (cDNA belonging from NCI-H295R cells was used
as internal positive control: DCt: 9.48 ± 0.57), thus suggesting
that PgR gene expression was present. Although a direct
relationship between mRNA and proteins cannot be
established, a correlation between the gene expression and the
immunofluorescent signal in these ACC cell models could be
observed. Indeed, PgR signal in MUC-1 cells and ACC115m
primary cell culture is weaker compared to NCI-H295R cells.
TABLE 1 | ER gene expression in ACC cell lines and primary cell culture.
Target gene NCI-H295R MUC-1 ACC115m
ER-a 10.88 ± 0.36 >15.00 11.50 ± 0.83
ER-b 9.81 ± 0.38 >15.00 13.43 ± 0.68
Values were reported as DCt that are differences of the threshold cycle (Ct) values between
the b-actin housekeeping gene and the gene of interest (DCt), calculated, as described in
Materials and Methods.
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These results are reported in Figure 4 and included NCI-H295R
cells as positive control. The immunofluorescence signal
quantification is reported in Supplemental Figure 5. A modest
cytotoxic effect of both ACC cell models derived from metastatic
patients was observed when cells were exposed to increasing Pg
concentrations, suggesting that these cells were less sensitive to
Pg compared to NCI-H295R cells. Indeed, the IC50 was 67.58 µM
(95% CI: 63.22–73.04 µM) for MUC-1 cells and 51.76 µM (95%
CI: 46.45–57.67 µM) for ACC115m cells (Figure 5A). Pg
treatment affected as well the cell proliferation rate on each
ACC cell model as reported in Figure 5B.
Effect of Drug Combined Treatment on
ACC Cell Viability
Due to the sensitivity of NCI-H295R cell line to both Pg and
tamoxifen, we thus evaluated whether the cytotoxic effect of
tamoxifen on NCI-H295R cell viability could be enhanced by Pg,
applying the Chou–Talalay method for drug combination
experiments (32, 33). Cells were exposed to increasing
concentrations of tamoxifen (1.2–13.5 µM) and Pg (7.4–84.3 µM)
at 1:6.17 fixed molar ratio for 4 days and then analyzed for cell
viability by MTT assay (Figure 6A). The combination index was
then calculated, and the analysis revealed a prevalent antagonist
effect when the two drugs were combined (Figure 6B). The
combination index value for each drug concentration is reported
in Supplemental Table 3, and the isobolograms are reported in
Supplemental Figure 5.
Finally, since mitotane is the standard treatment for ACC
patients, we then evaluated as well the combined treatment NCI-
H295R cell line with tamoxifen and mitotane. Results are
reported in Supplemental Figure 6, Supplemental Table 4
and showed that the combination has an additive/synergic
effect at low concentrations, while, as the drug concentrations





FIGURE 1 | ER expression in NCI-H295R, MUC-1 cell lines and ACC115m primary culture. Cells were seeded on poly-L-lysine pre-treated coverslips following by
incubation with DAPI for nuclear staining. Panel (A) DAPI; panel (B) phalloidin; panel (C) ER (red signal: ER-a; green signal: ER-b); panel (D) merge. The scale bar of
20 µm is automatically inserted by the software ZEN Black.
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Pg and Tamoxifen Reduced SF-1
Expression in NCI-H295R Cells
In order to evaluate the functional effect of Pg and tamoxifen in
the NCI-H295R cell line, the effect of these drugs on the
expression of the adrenal biomarker, namely SF-1, the
pleiotropic transcription factor involved as well in the
carcinogenesis (36) was studied. Cells were treated with Pg or
tamoxifen at their respective IC50 for 4 days and then the SF-1
A B
FIGURE 2 | Effect of tamoxifen on NCI-H295R cell viability and proliferation. (A) NCI-H295R were treated with increasing concentration of tamoxifen (0.1–20 uM)
and cell viability was then evaluated by MTT assay. Results are expressed as percent of viable cells vs ctrl ± SEM of three independent experiments run in triplicate.
(B) NCI-H295R were treated with low, intermediate, and high dose of tamoxifen and then cell proliferation was evaluated by directing counting with trypan blue
discrimination. *P < 0.0001 vs untreated cells; §P < 0.001 vs untreated cells.
A
B
FIGURE 3 | Tamoxifen exposure selectively modified the ER intracellular localization in NCI-H295R cells. (A) Cells were treated for different times with tamoxifen IC50
value. Slides were observed by a LSM 880 Zeiss confocal laser microscope or by a LSM 510 Zeiss confocal laser microscope (Carl Zeiss with 40× magnification.
Images were then reconstructed using Zeiss ZEN 2.3 Imaging Software (Carl Zeiss). On the left the ER-b staining, on the right ER-b + DAPI staining. (B) The specific
mean fluorescence intensity of the pixels of acquired images was quantified using ZEN Black software (Carl Zeiss). Several fields, randomly chosen, were acquired
and then analyzed for each experimental condition. Quantified analysis was conducted by GraphPad Prism 5.02 software. *P < 0.0001 vs ctrl; #P < 0.01 vs ctrl.
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expression was evaluated. Results are reported in Figure 7. By q-
RT-PCR, after Pg and tamoxifen treatment, no differences in the
SF-1 gene expression were detected (not shown), while
representative western blots were reported in Figure 7.1A. The
SF-1 protein expression was modified by both drugs: in
particular, as shown in Figure 7.1B, Pg treatment induced a
significant SF-1 reduction in NCI-H295R cell line (Pg: −36.34% ±
9.26%; tamoxifen: −46.25% ± 15.68%; P < 0.01).
In order to explain this phenomenon, we investigated the
expression of two miRNAs involved in SF-1 regulation, namely
miR23a and miR23b (37). The reduction of SF-1 protein
expression seemed to be mediated, at least in part, by the
increase of miRNA 23a expression, with an increase compared
to untreated cells of up to 1.54 ± 0.11 in Pg-treated cells and of
1.73 ± 0.04 in tamoxifen-treated cells respectively. An increase of
miRNA-23b expression was as well observed after tamoxifen
treatment (1.51 ± 0.02 compared to untreated cells), while this
miRNA did not seem to be involved in the regulation of SF-1
protein expression when NCI-H295R cells are exposed to Pg
(Figure 7.1C). SF-1 protein expression after Pg and/or tamoxifen
IC50 treatment was measured also in MUC-1 cell line, but no
significant variations were detected (Figures 7.2A, B).
PgR and ER Expression in ACC Tissues
Finally, the expression of ER and PgR was studied by
immunohistochemistry in 36 paraffin embedded tumor
samples belonging to ACC diagnosed patients. Among this
cohort, 13 patients were male and 22 female, with an age
median of 53 years (range: 16–79 years), 11 of them were





FIGURE 4 | PgR expression in NCI-H295R, MUC-1 cell lines and ACC115m primary culture. Cells were seeded on poly-L-lysine pre-treated coverslips following by
incubation with DAPI for nuclear staining. Panel (A) DAPI; panel (B) phalloidin; panel (C): PgR; panel (D): merge. The scale bar of 20 µm is automatically inserted by
the software ZEN Black.
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reported in Table 2 indicated that ERs were absent or present in
a very weak expression, while PgR proteins were expressed,
although with a variability within the different samples. In
particular, concerning the ER positive cells, we could observe
that only three ACC samples displayed a percentage of ER
moderately positive cells within the range of 30–69%, while 28
ACC displayed less than 5% ER positive cells, with a null o low
intensity. Concerning PgR, they presented an evaluable
expression in each sample studied, with only three ACC
expressing less than 5% of immunoreactive cells. Indeed,
almost half of samples expressed between 30 and 69% of
immune positive cells and eight samples up to 36 expressed
more than 70% of positive cells. A representative example of
immunohistochemistry conducted on some ACC tissues is
reported in Figure 8. The clinical characteristics are reported
in Supplemental Table 1. In detail, ACC29 cells showed a tumor
with lobulated morphology, moderate atypia and few mitotic
figures. This tumor exhibits focal and moderate PgR expression,
scant ER IR-cells, and low proliferation index. ACC32 cells
presented an epithelioid morphology with higher nuclear
atypia and prominent nucleoli. This tumor has few PgR IR
cells with faint staining intensity with no ER expression and
moderate proliferation index. ACC55 cells showed a solid growth
composed of clusters of eosinophilic cells with frequent nuclear
atypia and mitotic figures. Tumor has moderate PgR expression
with negative ER immunostaining and a labeling index up to
15%. The ACC91 cells had a solid growth composed by poorly
cohesive cell clusters with densely eosinophilic cytoplasm,
frequent nuclear atypia and mitosis. This tumor has a higher
expression of PgR along with moderate expression of ER.
Labeling index is higher between these samples, ranging from
15 to 20%.
A B
FIGURE 6 | Combined treatment tamoxifen plus Pg in NCI-H295R. (A) Concentration–response curve of tamoxifen, Pg, and drug combination in NCI-H295R. Cells
were exposed to increasing concentrations of tamoxifen and Pg alone or in combination as described in Materials and Methods. Data are expressed as percent of
viable cells vs ctrl. Data are the mean ± SEM of three independent experiments; *P < 0.0001 vs untreated cells; §P < 0.001 vs untreated cells. (B) Combination index
plot. Cell viability data of panel A were converted to Fa values and analyzed with CompuSyn software.
A B
FIGURE 5 | Cytotoxic effect of Pg in ACC cell models. (A) MUC-1 cell line and ACC115m primary culture were treated with increasing concentrations of
progesterone (0.1–160 uM), then cell viability was analyzed by MTT assay, (B) NCI-H295R, MUC-1 cell lines and ACC115m primary culture were treated with low,
intermediate, and high dose of Pg, and cell proliferation was analyzed by directing counting with trypan blue discrimination. Results are expressed as percent of
viable cells vs ctrl ± SEM; *P < 0.0001 vs untreated cells; #P < 0.01 vs untreated cells.
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DISCUSSION
In this study, we in vitro investigated whether the interplay
between ER, PgR, and their ligands may exert a cytotoxic and
antiproliferative activity on ACC experimental cell models as it
was demonstrated in endocrine-related cancers.
We observed that, although ER expression was relatively low,
tamoxifen exerted cytotoxic effect on NCI-H295R cell line,
belonging from a primitive ACC, confirming published data
(16). Drug exposure led to an increased nuclear localization of
ER-b subtype, with no modifications of the ER-a subcellular
localization, leading to the hypothesis that the cytotoxic and
antiproliferative effects of tamoxifen in ACC cells could be
mediated by its ER-b agonist activity, according to previous
observations (38). These results are in line with results showing
that in breast cancer cell lines stably expressing ER-b, this
receptor regulates multiple components normally associated
with the suppression of cell proliferation (i.e. TGFb and cell
cycle-related genes) (17). Thus, with these results, we supported
evidence indicating that ER-b is a protective factor that
suppresses uncontrolled proliferation and induces cell
differentiation in many tissues and organs, both in
physiological condition and in cancer degeneration (17).
However, the role of ERs in ACC cell models seemed to be
limited to the NCI-H295R cell line, as metastatic derived ACC
cell models such as MUC-1 and ACC115m expressed very weak
levels of both ER subtypes and were resistant to tamoxifen.
On the same line, this mechanism may have a scarce impact in
clinic, as our immunostaining data showed that ER is scarcely
expressed in paraffin-embedded ACC tissues as well as we
observed in ACC experimental cell models, accordingly with
those that detected low expression level of the ER subtypes in ACC.
The amount of ER expression in ACC seemed to decrease as
disease progresses, at least in our experimental cell models.
Indeed, as already underlined, in EDP-M resistant ACC cells,
namely MUC-1 and ACC115m cells, the expression of ER is very
low and cells do not respond to the SERM tamoxifen.
Accordingly, in our cohort of paraffin-embedded ACC
samples, the expression of ER was absent or present in a very
weak expression, thus limiting the possibility to explore a clinical
approach targeting ER in ACC patients. Another limitation
resides in the tamoxifen pharmacokinetic, as the calculated
plasma concentration at the steady state after 20 mg tamoxifen
for 3 months is about 0.3 µM, that is under the range of
concentrations that displayed a cytotoxic effect in our ACC
experimental cell models, although tamoxifen presents a
distribution volume that is about 50–60 l/kg (39).
Concerning PgR, immunohistochemical analysis of ACC
tissues strongly indicated that they are frequently expressed,
with a number of samples displaying a high percentage of
immunoreactive cells, although with a large variability among
samples. Accordingly, in a recent paper, our group demonstrated
that exposure to Pg of primary cells derived from PgR expressing
ACC (at least 40% of PgR+ cells) resulted in a concentration-
dependent increase of cytotoxicity (18) in line with results
demonstrating a role this hormone as anti-tumoral drug in
different cancers (40–42).
Here, we strengthen the role of PgR in the ACC and the effect
of Pg in reducing both cell proliferation and cell viability. This
effect seemed to be strictly related to the level of PgR expression,
thus the evaluation of the PgR expression during the pathological
staging could be of interest, as Pg and its derivative are already
part of the cancer supporting care, thus giving the opportunity




FIGURE 7 | Tamoxifen and Pg reduced the SF-1 expression in NCI-H295R cell line. (1A) Representative western blot of SF-1 expression after NCI-H295R
tamoxifen IC50 and Pg IC50 4 days treatment. (1B) Densitometric analysis of SF-1 expression after NCI-H295R drug treatment. Data are expressed as normalized
values SF-1/GAPDH and are the mean of three independent experiments. *P < 0.0001 vs ctrl; §P < 0.001 vs ctrl. (1C) NCI-H295R were treated with tamoxifen IC50
or Pg IC50 for 4 days and then miRNA23a/b expression was investigated. Data are expressed as normalized values on internal control U6 and are the mean of three
independent experiments. *P < 0.0001 vs ctrl; §P < 0.001 vs ctrl; #P < 0.01 vs ctrl. (2A) Representative western blot of SF-1 expression after MUC-1 tamoxifen IC50
and Pg IC50 5 days treatment. (2B) Densitometric analysis of SF-1 expression after MUC-1 drug treatment. Data are expressed as normalized values SF-1/GAPDH
and are the mean of three independent experiments.
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systemic therapy. This hypothesis is now under study in a
randomized phase II clinical trial.
The cross-talk between ER/PgR was detectable both at
physiological and pathological levels in endocrine tissues and
tumors (43). About it, it has been suggested that the combined
treatment using drugs targeting ER/PgR could be useful,
although the safety profile of the drug combination must be
considered (43). Thus, as published data support the rationale for
a synergism between anti-E and Pg in inducing an antineoplastic
effect, we tested the cytotoxic activity of the combination of
tamoxifen and Pg also in ACC experimental model of NCI-
H295R cells. Results obtained indicated that the tamoxifen/Pg
combination did not result in an either additive or synergic effect;
rather the resulting effect was of drug antagonism.
We finally investigated the functional effect of tamoxifen and
Pg exposure in ACC cell models, and we observed that both
drugs are able to decrease the protein expression of the ACC
biomarker SF-1, the transcription factor that is a critical
regulator of adrenogonadal development and function (44).
SF-1, also known as Ad4-binding protein or NR5A1, binds as
a monomer to nuclear receptor half sites on DNA (44), and it
plays an important role not only in adrenal steroidogenesis but
also in cell adhesion, cell proliferation, apoptosis, and
angiogenesis of adrenocortical tumor cells (36). Further,
Doghman et al. demonstrated that overexpression of SF-1 in
NCI-H295R increases proliferation rate (45). Thus, our results
on the downregulation of SF-1 protein expression during the
cytotoxic effect of tamoxifen and Pg on NCI-H295R cells found
their rationale on the pleiotropic role of SF-1. The reduction of
SF-1 protein expression along with a not significant modification
of SF-1 mRNA expression induced by both drugs, led us to
hypothesize that miRNA regulation of transcriptional capability
of mRNA could occurred. It is indeed known that miRNAs, by
binding to the 3′-untranslated region of target mRNAs, induced
translational repression followed by degradation of
approximately one-third of human genes (for an extensive
review see: 46). Using computational approaches, it is
suggested that each miRNA can bind to hundreds of different
mRNAs, which collectively results in an extremely fine
regulation of protein transcription (46). Thus, the concept that
TABLE 2 | Histological features and expression of PgR and ER in ACC tumor specimens.
code PgR ER
intensity % of IR cells cumulative intensity % of IR cells cumulative
ACC03 1 2 3 0 0 0
ACC04 2 3 5 1 0 1
ACC06 1 1 2 2 2 4
ACC07 2 3 5 2 2 4
ACC08 1 2 3 0 0 0
ACC10 3 3 6 2 1 3
ACC11 2 2 4 0 0 0
ACC12 1 1 2 1 0 1
ACC13 1 2 3 0 0 0
ACC14 1 2 3 1 1 2
ACC16 2 2 4 1 0 1
ACC17 1 0 1 0 0 0
ACC23 1 0 1 0 0 0
ACC24 2 2 4 0 0 0
ACC26 1 2 3 0 0 0
ACC27 1 2 3 1 0 1
ACC29 2 1 3 1 0 1
ACC30 2 3 5 0 0 0
ACC32 1 1 2 0 0 0
ACC38 2 2 4 1 0 1
ACC40 1 1 2 0 0 0
ACC48 1 2 3 2 2 4
ACC50 1 2 3 1 0 1
ACC55 1 1 2 0 0 0
ACC64 2 3 5 0 0 0
ACC68 2 3 5 0 0 0
ACC71 2 2 4 1 2 3
ACC74 2 2 4 0 0 0
ACC75 1 1 2 0 0 0
ACC79 1 0 1 0 0 0
ACC81 2 2 4 0 0 0
ACC85 1 3 4 0 0 0
ACC91 2 3 5 1 2 3
ACC99 1 2 3 0 0 0
ACC103 1 2 3 0 0 0
ACC115 1 1 2 0 0 0
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dysregulation of miRNA expression is linked to cancer is now
accepted worldwide. Among the cancer-associated miRNAs,
miR23a, one of the most studied miRNAs in different types of
cancer, has been found to be involved, together with miR23b, in
the regulation of SF-1 protein transcription (37). In NCI-H295R
cells, we demonstrated that SF-1 reduction could be mediated, at
least in part, by the increase of both miR23a and miR23b. The
mechanism underlying this inverse correlation between SF-1
protein and miR23a and miR23b expression is still unknown;
however, it has been shown that ER-a binding sites are present in
the regulatory region of miR23a (47, 48) and miR23b, along with
ER-b binding sites in miR23b regulatory region (49). To our
knowledge, no evidence of a direct regulation of Pg on miR23a
and miR23b is known at the moment; however, an indirect effect
of Pg acting on E-ER-miR23a and miR23b regulation could be as
well suggested, as it occurs for a large family of miRNAs in breast
cancer (50).
Taken together, these results suggest that SF-1 expression
seemed to be regulated by ER and PgR, These data, however, are
not exhaustive and the full evidence of the inhibitory effect would
require the demonstration of a modulation of the expression of
other specific b-catenin target genes in NCI-H295R cells by Pg
treatment. These further experiments are outside the scope of the
present paper and will be a matter of a future study.
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